Skip to main content
Premium Trial:

Request an Annual Quote

Mark Chee, Karoly Nikolich, David Lockhart, Mostafa Ronaghi, Jeffrey Trent, Tracy Warren, Edward Erickson

Premium
Febit has formed a scientific advisory board. The board will be chaired by Mark Chee, CEO of Prognosys Biosciences, a collaborator of Febit. Chee is a co-founder of Illumina and a former Affymetrix scientist.
 
The other members are Karoly Nikolich, an entrepreneur and consultant, and the former executive director of the Neuroscience Institute of Stanford; David Lockhart, CSO of Amicus Therapeutics and a former Affymetrix employee; Mostafa Ronaghi, a senior research associate at the Stanford University Genome Technology Center and an inventor of pyrosequencing; and Jeffrey Trent, president and scientific director of the Translational Genomics Research Institute
 

 
Tracy Warren and Edward Erickson are joining the board of directors of BioNanomatrix, following the company’s recent $5.1 million Series A funding round (see Short Reads, in this issue). Warren is a general partner of Battelle Ventures, the lead investor in the round, and Erickson has “extensive experience” in the medical products industry, according to BioNanomatrix.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.